FLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for ...

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...

The vaccine could give Moderna a foothold in seasonal flu and strengthen the case for mRNA shots against fast-changing ...

The FDA approved Moderna’s flu vaccine mFLUSIVA, a regulatory decision that comes six months after the agency refused to ...

The decision caps a seven-month process that included a rare refusal to consider the shot.

The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

The FDA has approved Moderna's mRNA-based seasonal flu vaccine for adults 50 and older, marking the first such approval in the U.S.

The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, ​and an accelerated approval for ​those 65 ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...

The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.